FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Agitation in Alzheimer's: Rexulti® Makes Meaningful Improvements

Ask the Pharmacist: New drug treats Alzheimer's agitation, Health

FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation - Southern Iowa Mental Health Center

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

FDA Approves Rexulti for Treating Agitation Due to Alzheimer's - MyChesCo

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

Agitation in Alzheimer's Disease: Expert Tips for Caregivers

Articles about Otsuka America Pharmaceutical, Inc.

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease

FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease

Researcher finds help for Alzheimer's-associated agitation with new FDA- approved treatment

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease